E-mail: heinz.gisslinger@meduniwien.ac.at
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM)
- BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE FOR TREATMENT OF RELAPSED/REFRACTORY MYELOMA
- Bortezomib-Doxorubicin-Dexamethasone (BDD) for Reversal of Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Results from a Phase II Study
- Bortezomib-Doxorubicin-Dexamethasone (BDD) in Patients with Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Final Results of a Phase II Study
- Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy
- Final Results of the ANAHYDRET-Study: Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed WHO-Essential Thrombocythemia Patients
- Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Study
- Heterogenity of Myeloproliferative Disorders: Genetic Basis, Clonal Complexity, and Implications for Therapy
- HIGH RESOLUTION CYTOGENETIC MAPPING AND WHOLE EXOME SEQUENCING REVEAL A COMPLEX PATTERN OF CHROMOSOME 6P ABERRATIONS IN PATIENTS WITH MYELOID MALIGNANCIES
- Characterization of Chromosome 20q Deletions In Myeloproliferative Neoplasms Using Microarray Karyotyping and Next-Generation Sequencing
- Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient
- Long-Term Experience with Anagrelide (Thromboreductin®) In the Treatment of Essential Thrombocythemia: Data from an International Registry
- Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed Patients with Essential Thrombocythemia: The ANAHYDRET-Study.
- PROGNOSTIC SIGNIFICANCE OF GENETIC ABERRATIONS IN SECONDARY ACUTE MYELOID LEUKEMIA
- Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study.
- Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study
- THALIDOMIDE-DEXAMETHASONE VERSUS MELPHALAN-PREDNISOLONE AS FIRST LINE TREATMENT IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA: AN INTERIM ANALYSIS
- Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.
- Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma
- The Role of JAK2-V617F Oncogenic Mutation in Thrombosis Associated with Myeloproliferative Disorders
- Whole Exome Sequencing Identifies Novel MPL and JAK2 Mutations in Triple Negative Myeloproliferative Neoplasms
